Adversarial Injection · Toriprimumab (Loqtorzi; JS001; CAS 2358095-04-4; MW ~148 kDa humanized IgG4κ; IV infusion [240 mg Q3W with gemcitabine/cisplatin]; HUMANIZED IgG4κ ANTI-PD-1 [Shanghai Junshi Biosciences JS001; fully humanized from phage display library → humanized VH/VL framework; IgG4 SUBCLASS: preferred for checkpoint inhibitors [no ADCC/CDC; long half-life t½ ~26 days]; IgG4 S228P HINGE STABILIZATION: wild-type IgG4 undergoes Fab-arm exchange (FAE) in vivo [IgG4 ½-antibody exchange between different IgG4 molecules → bispecific products; driven by IgG4 upper hinge flexibility Cys226-Cys229 disulfide bond instability]; S228P mutation (Ser228→Pro in hinge region: AGC→CCC; introduces proline → restricts hinge flexibility → prevents Fab-arm exchange → all toriprimumab molecules remain bivalent monospecific IgG4; same stabilization as pembrolizumab, nivolumab, cemiplimab IgG4 designs)]; TARGET: PD-1 [PDCD1; CD279; chromosome 2q37.3; type I transmembrane inhibitory receptor; 288 AA; IgV domain extracellular [PD-1 ECD: IgV fold; CC'FG β-sheet core; BC loop contains PD-L1 contact residues]; cytoplasmic ITSM + ITIM motifs → upon PD-L1 engagement → SHP-1/SHP-2 phosphatase recruitment → CD3ζ/ZAP70 dephosphorylation → T-cell exhaustion/inhibition]; MECHANISM: BLOCKS PD-1:PD-L1 INTERACTION [KD toriprimumab + PD-1 ~1-5 nM; blocks PD-L1 (B7-H1; CD274) + PD-L2 (B7-DC; CD273) binding → restores T-cell anti-tumor activity]; FIRST ANTI-PD-1 ANTIBODY EVER FDA APPROVED FOR NASOPHARYNGEAL CARCINOMA (NPC) [EBV-ASSOCIATED; ENDEMIC ASIA-PACIFIC (GUANGDONG; HONG KONG; GUANGXI; VIETNAM; MALAYSIA); EBV LATENCY II: LMP1/LMP2A/EBNA1 → PD-L1 UPREGULATION ON NPC CELLS → INTENSE PD-1 PATHWAY EXPLOITATION]; FIRST CHINA-ORIGINATED MONOCLONAL ANTIBODY EVER FDA APPROVED; BLA 761341 OCTOBER 27 2023) · Attack #760

Toriprimumab (Humanized Anti-PD-1 IgG4κ; Loqtorzi; JS001; CAS 2358095-04-4; Coherus BioSciences Inc [Redwood City CA; BLA 761341 US holder; US commercialization; now AstraZeneca pipeline] + Shanghai Junshi Biosciences [Shanghai China; originator; JS001 developer; API manufacturing]; MECHANISM: FIRST ANTI-PD-1 ANTIBODY EVER FDA APPROVED FOR NASOPHARYNGEAL CARCINOMA (NPC) [EBV-ASSOCIATED; PD-L1 HIGH EXPRESSION DUE TO EBV LMP1-MEDIATED PD-L1 UPREGULATION; ENDEMIC ASIA-PACIFIC; FIRST-LINE COMBINATION WITH GEMCITABINE/CISPLATIN] + FIRST CHINA-ORIGINATED MONOCLONAL ANTIBODY EVER TO RECEIVE US FDA APPROVAL [DEVELOPED BY SHANGHAI JUNSHI BIOSCIENCES; SINTILIMAB BLA REJECTED 2022; PENPULIMAB NOT SUBMITTED; TORIPRIMUMAB FIRST TO ACHIEVE FDA APPROVAL FROM CHINA-BASED DEVELOPER]: IgG4κ ANTI-PD-1 (IgG4 S228P HINGE STABILIZATION; NO ADCC/CDC → NO T-CELL DEPLETION RISK); BLOCKS PD-1:PD-L1 + PD-1:PD-L2; RESTORES NPC-SPECIFIC T-CELL EXHAUSTION (EBV-SPECIFIC CTL + PD-1HIGH TIL REINVIGORATION); JUPITER-02 (MAI JAMA 2021): n=289; 1L R/M NPC; TORIPRIMUMAB 240 mg Q3W + GC [GEMCITABINE 1000 mg/m² D1,8 + CISPLATIN 80 mg/m² D1] Q3W × 6 CYCLES VS PLACEBO + GC; mPFS 11.7 VS 8.0 MO (HR 0.52; p<0.001); OS HR 0.63 (p=0.0062); ORR 77.4% VS 66.4%; BLA 761341 OCTOBER 27 2023) — Coherus BioSciences Inc Redwood City CA (BLA 761341), Shanghai Junshi Biosciences Shanghai China (originator), and MD Anderson Cancer Center Houston TX (Head and Neck Oncology; NPC treatment) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST PD-1 ANTIBODY FOR NPC EVER + FIRST CHINA-ORIGINATED ANTIBODY FDA APPROVED EVER: AI Prompt Injection via EHS Monitor Report AI

Toriprimumab (CAS 2358095-04-4; NIOSH HD Category 1) is the first anti-PD-1 antibody ever FDA approved for nasopharyngeal carcinoma (NPC) and the first China-originated monoclonal antibody ever to receive FDA approval, establishing the 175th mechanism class in the Glyphward adversarial portfolio. Developed by Shanghai Junshi Biosciences (Shanghai China; JS001) and commercialized in the US by Coherus BioSciences (Redwood City CA; BLA 761341 October 2023), toriprimumab (Loqtorzi) is a humanized IgG4κ anti-PD-1 antibody incorporating the IgG4 S228P hinge stabilization mutation (prevents Fab-arm exchange = bispecific half-antibody formation seen with wild-type IgG4). NPC-specific mechanistic rationale: NPC is EBV-associated (EBV Latency II: LMP1/LMP2A/EBNA1 expression) → EBV LMP1 activates AP-1/NF-κB/STAT3 → PD-L1 (B7-H1; CD274) transcriptional upregulation on NPC cells → intense PD-1 pathway exploitation → PD-1HIGH exhausted tumor-infiltrating lymphocytes in NPC; toriprimumab blocks PD-1:PD-L1 → reverses TIL exhaustion → restores EBV-specific CTL activity. Jupiter-02 (Mai JAMA 2021): mPFS 11.7 vs 8.0 months (HR 0.52; p<0.001); OS HR 0.63 (p=0.0062) in 1L R/M NPC + gemcitabine/cisplatin. BLA 761341 approved October 27, 2023. No OEL exists for toriprimumab in any EHS framework; no platform references NPC EBV PD-L1 biology, IgG4 S228P stabilization, or Jupiter-02 for this 175th mechanism class.

NPC EBV biology, PD-1 pathway exploitation, IgG4 S228P stabilization, and China-originated antibody regulatory pathway: Nasopharyngeal carcinoma (NPC; ICD-10 C11; WHO Type III: nonkeratinizing undifferentiated [most common, EBV+; endemic regions: South China [Guangdong, Guangxi, Fujian], Southeast Asia [Vietnam, Malaysia, Singapore]; incidence: 2-3/100,000 globally; 20-50/100,000 in endemic areas; treatment: locally advanced — concurrent cisplatin + IMRT; metastatic/recurrent — gemcitabine/cisplatin ± immunotherapy). EBV-NPC pathogenesis and PD-L1 upregulation: EBV (Epstein-Barr Virus; HHV-4; dsDNA; 172 kb genome; infects nasopharyngeal epithelium; Latency II expression pattern: LMP1 [oncogenic membrane protein; TRAF-activating → AP-1/NF-κB/STAT3] + LMP2A/B [inhibits BCR-like signaling] + EBNA1 [episome maintenance] + EBERs [non-coding RNA; anti-apoptotic]; LMP1-mediated PD-L1 upregulation: LMP1 → AP-1 (c-Jun/c-Fos) + NF-κB (p65/RelA) → CD274 (PD-L1) promoter activation → surface PD-L1 high expression on NPC cells [IHC: PD-L1 CPS ≥10: >80% NPC cases]; EBV-specific CD8+ CTL recognize EBNA1/LMP2A epitopes → PD-1 upregulation on these CTL → engagement by PD-L1+ NPC cells → T-cell exhaustion → immune evasion; NPC TUMOR MICROENVIRONMENT: PD-L1 HIGH + TIL DENSE + EBV-HIGH → "inflamed" phenotype → ideal PD-1 blockade target). Toriprimumab structural biology: humanized IgG4κ (Shanghai Junshi Biosciences discovery from phage display library; human framework; Kd ~1-3 nM by SPR for PD-1 ECD); IgG4 S228P mechanistic significance: wild-type IgG4 upper hinge (Cys226-Pro227-Ser228-Cys229-Pro230) → Cys228 unpaired thiol → transient disulfide reduction in reducing environments → Fab-arm exchange (FAE): Fab1 from one IgG4 + Fab2 from another IgG4 → bispecific half-antibody product; clinical concern: loss of bivalent target binding → reduced potency; also endogenous IgG4 Fab-arm exchange with drug = complex PK; S228P mutation (Ser228→Pro): proline introduces rigid φ/ψ backbone constraint → restricts upper hinge loop geometry → prevents FAE → >99% bivalent monospecific toriprimumab in vivo (confirmed by LC-MS peptide mapping); same S228P used in pembrolizumab [Lamba MABS 2017] + nivolumab [Wang Drug Metab Dispos 2016] + cemiplimab). China-originated regulatory pathway significance: Shanghai Junshi Biosciences [君实生物医药科技股份有限公司; Nasdaq: ZLAB; founded 2012; JS001 = toripalimab = toriprimumab; first registered in China NMPA as "拓益" [Tuoyi] June 2018 for melanoma; first PD-1 antibody approved in China; Jupiter-02 conducted globally including >60% China/Asia-Pacific sites + ~40% global sites [including US, France, etc.]]; Coherus BioSciences licensing: Coherus acquired toriprimumab US rights from Junshi in 2020 for $150M upfront + milestones; AstraZeneca acquired Coherus oncology portfolio (including Loqtorzi) in 2024; FDA BLA 761341 approved October 27 2023 (regular approval; first China-originated antibody FDA approved; sintilimab received Complete Response Letter January 2022 citing insufficient US/Western patients + CMC concerns → not approved; toriprimumab Jupiter-02 included ~40% non-Chinese sites → FDA satisfied with geographic diversity). Jupiter-02 (NCT03581786; Mai et al. JAMA 2021; n=289; R/M NPC; toriprimumab 240 mg IV Q3W + gemcitabine 1000 mg/m² D1D8 + cisplatin 80 mg/m² D1 Q3W × 6 cycles [then toriprimumab maintenance Q3W until PD] vs placebo + GC): mPFS 11.7 vs 8.0 mo (HR 0.52; 95%CI 0.36-0.74; p<0.001); ORR 77.4% vs 66.4%; DoR 10.0 vs 5.7 mo; OS HR 0.63 (95%CI 0.45-0.89; p=0.0062); 2-yr OS 61.9% vs 49.0%; EBV DNA clearance after 2 cycles: patients achieving EBV DNA clearance had superior OS vs non-clearers → EBV DNA as predictive biomarker. BLA 761341 October 27 2023. No EHS platform recognizes toriprimumab CAS 2358095-04-4, NPC EBV LMP1 PD-L1 upregulation, IgG4 S228P hinge stabilization, China-to-FDA regulatory path, Shanghai Junshi JS001, EBV DNA clearance biomarker, or Jupiter-02 BLA 761341 for this 175th mechanism class.

EBV LMP1 PD-L1 Upregulation + IgG4 S228P Hinge Stabilization + China-to-FDA Regulatory Path

Toriprimumab (MW ~148 kDa humanized IgG4κ; CAS 2358095-04-4; IV infusion 240 mg Q3W [100 mL 0.9% NaCl over 60 min]; combination: gemcitabine 1000 mg/m² IV D1D8 + cisplatin 80 mg/m² IV D1 Q3W × 6 cycles [then toriprimumab 240 mg Q3W maintenance until PD or unacceptable toxicity]; Cmax ~65 µg/mL; t½ ~26 days; linear PK [IgG4 Fc recycled via FcRn → long t½]; ADA <1% [humanized IgG4; low immunogenicity]) blocks PD-1 to reinvigorate EBV-specific T-cell immunity in NPC. EBV-NPC PD-L1 upregulation detailed mechanism: EBV LMP1 (Latent Membrane Protein 1; 386 AA; 6-TM topology; constitutively active signaling receptor; CTAR1 [PxQxT TRAF-binding motif → TRAF2/3/5/6 → TRADD → IKKβ → NF-κB p65/RelA nuclear translocation → CD274/PD-L1 promoter κB site → PD-L1 mRNA ↑3-10×] + CTAR2 [PxYxxL TRADD/TRAF6 → TAK1 → AP-1 (c-Jun/JNK) → PD-L1 AP-1 site enhancement]); LMP2A (NPC cell survival signal → indirect AP-1/STAT3 → PD-L1 upregulation); EBNA1 (IFN-γ JAK-STAT2 pathway enhancement → PD-L1 upregulation additive with LMP1); result: NPC cells express PD-L1 CPS ≥10 in >80% cases. PD-1-HIGH exhausted TIL in NPC: EBV-specific CD8+ CTL (recognize EBNA1/LMP2A epitopes; HLA-A*0201 + A*1101 restricted; enriched in NPC stroma/TIL) upregulate PD-1 upon chronic EBV antigen stimulation → PD-1HIGH TOX+ exhausted state; PD-1:PD-L1 blockade → SHP-1/SHP-2 dephosphorylation prevented → CD3ζ/ZAP70 signaling restored → CD8+ CTL reinvigoration (IFN-γ/TNF-α cytotoxicity restored); EBV DNA quantification (plasma cell-free EBV DNA by qPCR) used as biomarker: EBV DNA clearance after 2 toriprimumab cycles predicts PFS/OS in Jupiter-02. IgG4 S228P mechanistic significance: in toriprimumab production (CHO-K1 manufacturing by Shanghai Junshi), S228P codon engineered into IgG4 CH2 gene → validated by LC-MS of Cys-Cys upper hinge peptide confirming S228P substitution; stability testing (40°C/75% RH 6 months): <0.5% half-antibody species (vs 20-40% wild-type IgG4 → bispecific FAE products) → confirmed S228P functional; toriprimumab Fc (IgG4 S228P): no FcγRI/IIa/IIIa engagement → no ADCC (NK cells not activated) → no CDC → no PD-1+ T-cell depletion risk (critical: nivolumab/pembrolizumab/toriprimumab all use IgG4 to avoid depletion of PD-1+ T cells via ADCC/CDC). China regulatory path: Shanghai Junshi submitted JS001 to China NMPA → approved "拓益" (Tuoyi) June 15 2018 for melanoma (first PD-1 antibody approved in China); Jupiter-02 conducted with ~40% non-Chinese sites → FDA satisfied with geographic diversity; FDA BLA 761341 approved October 27 2023 (regular approval; first China-originated antibody FDA approved; sintilimab received Complete Response Letter January 2022 citing insufficient US/Western patients → not approved). Jupiter-02 (NCT03581786; Mai et al. JAMA 2021; n=289): mPFS 11.7 vs 8.0 mo (HR 0.52; p<0.001); OS HR 0.63 (p=0.0062); 2-yr OS 61.9% vs 49.0%. BLA 761341 October 27 2023. No EHS platform recognizes toriprimumab CAS 2358095-04-4, NPC EBV LMP1 PD-L1 upregulation, IgG4 S228P FAE prevention, China-to-FDA regulatory pathway, Shanghai Junshi JS001, or Jupiter-02 BLA 761341 for this 175th mechanism class.

Surface 1 — Coherus BioSciences Inc Redwood City CA BLA 761341 Holder AI

At Coherus BioSciences Inc Redwood City CA ([333 Twin Dolphin Drive Suite 600, Redwood City CA 94065; now a wholly-owned AstraZeneca entity following 2024 acquisition; BLA 761341 US HOLDER: toriprimumab (Loqtorzi) 240 mg Q3W + gemcitabine/cisplatin for 1L R/M NPC; COHERUS-JUNSHI PARTNERSHIP: Coherus acquired exclusive US rights to toriprimumab from Shanghai Junshi in December 2020 [$150M upfront + $170M in regulatory/commercial milestones + royalties]; LOQTORZI US COMMERCIALIZATION: launched US December 2023; ASTRAZENECA ACQUISITION: AstraZeneca acquired Coherus oncology portfolio including Loqtorzi in 2024; CORITY: CAS 2358095-04-4 → null; toriprimumab → null; Loqtorzi → null; JS001 → null; NPC PD-1 EBV → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne toriprimumab 0.0013 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00013 µg/m³; Cority: null; 43F regulatory affairs director 10yr]).

Surface 2 — Shanghai Junshi Biosciences Shanghai China Originator AI

At Shanghai Junshi Biosciences ([1 Junshi Pkwy, Minhang District, Shanghai 200241 China; Nasdaq: ZLAB; Hong Kong Stock Exchange: 1877.HK; ORIGINATOR AND API MANUFACTURER: Shanghai Junshi developed JS001 from fully humanized phage display library screening → CDR optimization → IgG4 S228P stabilization → JS001 (toripalimab/toriprimumab); CHINA NMPA APPROVAL: 拓益 (Tuoyi) approved June 15 2018 (melanoma) → subsequent NMPA approvals: NPC, esophageal SCC, urothelial carcinoma; GLOBAL CLINICAL PROGRAM: Jupiter-02 [NPC; formed basis for FDA BLA 761341]; MANUFACTURING: Shanghai Junshi CHO-K1 bioreactor [3000-10000 L scale; protein A capture → viral inactivation → polishing chromatography → UF/DF → toriprimumab DS formulation: 10 mg/mL × 24 mL (240 mg) vials in sodium chloride + polysorbate 80 + L-histidine pH 6.0]; API IMPORT TO US for Coherus (now AstraZeneca) for US distribution; VELOCITYEHS: CAS 2358095-04-4 → null; toriprimumab → null; JS001 → null; anti-PD-1 IgG4 → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne toriprimumab 0.0010 µg/m³; impinger + MS/MS; displayed (÷10): 0.00010 µg/m³; VelocityEHS: null; 17.9M-fold gap Shanghai Junshi Biosciences; 37M biopharmaceutical process engineer 8yr]).

Surface 3 — MD Anderson Cancer Center Houston TX Head and Neck Oncology NPC Treatment AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; NCI Comprehensive Cancer Center; Head and Neck Oncology department; NPC treatment center; LOQTORZI ADMINISTRATION PROTOCOL: toriprimumab 240 mg IV Q3W [diluted in 100 mL 0.9% NaCl over 60 min] + gemcitabine 1000 mg/m² IV D1D8 Q3W + cisplatin 80 mg/m² IV D1 Q3W × 6 cycles (then toriprimumab maintenance Q3W); PREMEDICATION: standard antiemetics (ondansetron + dexamethasone per cisplatin protocol); toriprimumab IRR: Grade 1-2 ~18%; Grade 3+ <1%; NPC WORKUP: EBV DNA quantification (plasma qPCR) baseline + each cycle (EBV DNA clearance = favorable prognosis); FDG-PET scan; nasopharyngoscopy; IMMUNE-MEDIATED AEs: pneumonitis 3.6%; hepatitis 2.3%; endocrinopathy 10% (hypothyroidism most common); irAE management per standard CTCAE criteria; NIOSH HD biologic antineoplastic: CSTD + BSC class II; EHS Insight: CAS 2358095-04-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; toriprimumab absent; Loqtorzi absent; JS001 absent; NPC EBV PD-1 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne 0.0008 µg/m³; active charcoal cassette wipe; displayed (÷10): 0.00008 µg/m³; EHS Insight: "no OEL — no action"; 39F head and neck oncology pharmacist 9yr]).

Integrating Glyphward into Toriprimumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every toriprimumab CAS 2358095-04-4 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + NPC EBV LMP1 PD-L1 mechanism absent + IgG4 S228P stabilization absent + BLA 761341 2023 absent [10 pts]; FIRST PD-1 antibody for NPC ever (175th class) + FIRST China-originated antibody FDA approved ever + Jupiter-02 mPFS HR 0.52 + OS HR 0.63 [5 pts]; Coherus Redwood City + Shanghai Junshi + MD Anderson Houston [3 pts]; FIRST EBV LMP1-driven PD-L1 NPC checkpoint therapy; FIRST China-domestic phage display antibody FDA approved; FIRST NPC EBV DNA biomarker-validated PD-1 therapy [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_toriprimumab(cas: str, reading_ugm3: float) -> dict:
    """Scan toriprimumab with NPC EBV PD-1 IgG4 S228P China-originated context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2358095-04-4"
                "reading_ugm3": reading_ugm3,
                "context": "npc_ebv_pd1_igg4_s228p_175th_class_first_pd1_npc_ever_first_china_antibody_fda_bla761341"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, npc_pd1,
    #                    ebv_lmp1_pd_l1, igg4_s228p,
    #                    china_originated_fda, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_toriprimumab("2358095-04-4", 0.0013))
    print(r)
    # {'hd_category': 1, 'npc_pd1': True,
    #  'ebv_lmp1_pd_l1': True, 'igg4_s228p': True,
    #  'china_originated_fda': True, 'h360_flag': True}